Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.

ABSTRACT: Unlike many conventional cancers with preferential patterns of oncogenic genetic alterations, TRK fusions resulting from NTRK1/2/3 genetic alterations drive oncogenic transformations in more than 20 different malignancies over diverse tissue/cell lineages, in both children and adults. A recent "basket" study of larotrectinib, a TRK inhibitor, has demonstrated significant efficacy in TRK fusion-positive tumors of all types from infants to the elderly. Here, we discuss the larotrectinib study and perspectives and challenges in developing "tumor-agnostic" targeted therapies in rare tumors.

SUBMITTER: Chen Y 

PROVIDER: S-EPMC5992878 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature